propranolol has been researched along with Pain, Chronic in 2 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Excerpt | Relevance | Reference |
---|---|---|
"Propranolol's efficacy in reducing facial pain index was greater among the 104 migraineurs than the 95 non-migraineurs: For example, for the binary ≥ 30% reduction in facial pain index, odds ratios were 3." | 5.41 | Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial. ( Arbes, SJ; Campbell, JH; Fillingim, RB; Giosia, MD; Hadgraft, H; Lim, PF; Ohrbach, R; Ribeiro-Dasilva, M; Slade, GD; Tchivileva, IE; Willis, J, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Tchivileva, IE | 1 |
Ohrbach, R | 1 |
Fillingim, RB | 2 |
Lim, PF | 1 |
Giosia, MD | 1 |
Ribeiro-Dasilva, M | 1 |
Campbell, JH | 1 |
Hadgraft, H | 1 |
Willis, J | 1 |
Arbes, SJ | 1 |
Slade, GD | 1 |
George, SZ | 1 |
Staud, R | 1 |
Borsa, PA | 1 |
Wu, SS | 1 |
Wallace, MR | 1 |
Greenfield, WH | 1 |
Mackie, LN | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder[NCT02437383] | Phase 2 | 200 participants (Actual) | Interventional | 2015-08-20 | Completed | ||
Biopsychosocial Influence on Shoulder Pain: a Randomized, Pre-clinical Trial[NCT02620579] | Phase 2 | 264 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | mm Hg (Least Squares Mean) |
---|---|
Propranolol ER | -3.3 |
Placebo | 1.0 |
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | beats per minute (Least Squares Mean) |
---|---|
Propranolol ER | -3.9 |
Placebo | 1.5 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | mm (Least Squares Mean) |
---|---|
Propranolol ER | -0.3 |
Placebo | -0.8 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | mm (Least Squares Mean) |
---|---|
Propranolol ER | -0.9 |
Placebo | -1.2 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | mm (Least Squares Mean) |
---|---|
Propranolol ER | 4.5 |
Placebo | 1.4 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of lateral epicondyle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | kPa (Least Squares Mean) |
---|---|
Propranolol ER | 41.4 |
Placebo | 22.7 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of masseter muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/- 7)
Intervention | kPa (Least Squares Mean) |
---|---|
Propranolol ER | 38.3 |
Placebo | 29.3 |
Pressure values, measured in kilopascals (kPa), from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporalis muscle, are averaged to obtain a single pressure pain threshold value per anatomical site. The range is 0-500 kPa and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | kPa (Least Squares Mean) |
---|---|
Propranolol ER | 41.8 |
Placebo | 38.4 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporomandibular joint, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | kPa (Least Squares Mean) |
---|---|
Propranolol ER | 36.8 |
Placebo | 25.3 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of trapezius muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | kPa (Least Squares Mean) |
---|---|
Propranolol ER | 64.1 |
Placebo | 63.3 |
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | mm Hg (Least Squares Mean) |
---|---|
Propranolol ER | -3.6 |
Placebo | 1.3 |
"The HIT-6 contains 6 items and assesses headache-related disability by the frequency of daily activity limitations ranging from never to always. The 6 item scores are summed to yield a global score ranging from 36 to 78. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -5.1 |
Placebo | -3.1 |
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -1.3 |
Placebo | -0.7 |
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -1.0 |
Placebo | -0.6 |
"The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = no limitation and 10 = severe limitation. The Global Score is computed as the mean response for all items and ranges from 0 to 10. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -1.1 |
Placebo | -0.8 |
"The PSS assesses the frequency of 14 sources of stress on a scale from 0 = never to 4 = very often. The item scores are summed to yield a global score ranging from 0 to 56. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -2.6 |
Placebo | -1.9 |
The PSQI has 19 items grouped into 7 component scores, each weighted equally on a 0-3 scale, The 7 component scores are summed to yield a global PSQI score, which has a range of 0-21. A higher score means a worse outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -0.7 |
Placebo | -1.0 |
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | 3.6 |
Placebo | 2.8 |
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | 1.2 |
Placebo | 0.3 |
"The SF-McGill Pain Questionnaire contains 4 affective descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 12. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -2.9 |
Placebo | -3.1 |
"Self-reported present intensity of facial pain at the moment of assessment scored on a descriptive scale where 1 = no pain' and 6 = excruciating pain. A higher score means worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -0.9 |
Placebo | -0.7 |
"The SF-McGill Pain Questionnaire contains 11 sensory descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 33. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -1.9 |
Placebo | -1.6 |
"Self-reported average facial pain duration for the last week scored on 0-100 percentage scale where percent = percent of waking day you had facial pain. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -23.6 |
Placebo | -21.6 |
"Self-reported average facial pain intensity for the last week scored on 0-100 numerical rating scale where 0 = no pain and 100 = the most intense pain imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -18.2 |
Placebo | -15.8 |
"Self-reported average fatigue for the last week scored on 0-100 numerical rating scale where 0 = no fatigue and 100 = the greatest imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -12.0 |
Placebo | -11.4 |
"The SCL-90R Somatization Scale is a 12-item assessment of somatic symptom distress over the past 7 days rated from 0 = not at all to 4 = extremely. The scale score is computed as the mean for all items. The score range is from 0 to 4. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -0.2 |
Placebo | -0.2 |
"Weekly mean pain duration computed as the arithmetic mean of daily pain duration values during the week prior to randomization and prior to each study visit. Daily pain duration is measured on 0-100 percentage scale where percent = percent of waking day you had facial pain as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -17.9 |
Placebo | -16.6 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary and divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -13.9 |
Placebo | -12.1 |
"Weekly mean pain intensity computed as the arithmetic mean of daily pain intensity values during the week prior to randomization and prior to each study visit. Daily pain intensity is measured on 0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Propranolol ER | -17.1 |
Placebo | -13.6 |
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain threshold (temperature at which pain is first perceived). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | degrees Celsius (Least Squares Mean) |
---|---|
Propranolol ER | 1.3 |
Placebo | 0.5 |
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain tolerance (temperature at which pain can no longer be tolerated). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | degrees Celsius (Least Squares Mean) |
---|---|
Propranolol ER | 0.5 |
Placebo | 0.4 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) Low Pain Sensitive (LPS) haplotypes." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
0 LPS haplotypes | 1 LPS haplotype | 2 LPS haplotypes | |
Placebo | -12.3 | -13.2 | -2.5 |
Propranolol ER | -14.2 | -12.2 | -15.2 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) valine alleles at single nucleotide polymorphism (SNP) rs4680." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
0 valine alleles | 1 valine allele | 2 valine alleles | |
Placebo | -13.9 | -13.1 | -9.7 |
Propranolol ER | -14.2 | -13.9 | -14.3 |
The Brief Pain Inventory (BPI) consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). BPI will be recorded daily and the recovery criterion used for this study will be a BPI rating of current pain 0/10 and worst pain rating of less than 2/10. The pain duration is number of days from the date of induced pain to date of recovery. The longer the duration means a worse outcome. (NCT02620579)
Timeframe: Daily until recovery criterion met, approximately 5-15 days
Intervention | days (Median) |
---|---|
Personalized Pharmaceutical and Education (C) | 4 |
Placebo Pharmaceutical, General Education (B) | 4 |
Placebo Pharmaceutical, Personalized Education (A) | 4 |
Personalized Pharmaceutical, General Education (D) | 4 |
The Brief Pain Inventory (BPI) which consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). Participants will rate their current, best, and worst pain intensity on the BPI. This measure will be recorded daily through study completion, an average of 5 days. The worst pain intensity rating at Day 2 (when participants usually had the Peak Shoulder Pain Intensity) is reported. (NCT02620579)
Timeframe: Day 2 value of the worst pain intensity is reported
Intervention | score on a scale (Mean) |
---|---|
Personalized Pharmaceutical and Education (C) | 2.9 |
Placebo Pharmaceutical, General Education (B) | 3.2 |
Placebo Pharmaceutical, Personalized Education (A) | 2.9 |
Personalized Pharmaceutical, General Education (D) | 3.1 |
The abridged version of the DASH (the QuickDASH) which consists of 11 functional items, with total scores ranging from 0 (not disability) to 100 (complete disability) will be used to assess upper-extremity disability. The primary outcome will be the highest DASH score recorded during the pain intensity recovery period. (NCT02620579)
Timeframe: Daily until recovery criterion met, approximately 5-15 days
Intervention | score on a scale (Mean) |
---|---|
Personalized Pharmaceutical and Education (C) | 8.2 |
Placebo Pharmaceutical, General Education (B) | 10.5 |
Placebo Pharmaceutical, Personalized Education (A) | 11.4 |
Personalized Pharmaceutical, General Education (D) | 9.4 |
The outcome has a range between 0 and 1, the higher scores mean a better outcome. Successful recovery was determined based on meeting the recovery criterion for shoulder pain intensity by at least 6 days. Specifically, recovery (Yes or No) was defined using Brief Pain Inventory (BPI) ratings as a current pain intensity rating of 0/10 and a worst pain intensity rating of less than 2/10. (NCT02620579)
Timeframe: Approximately 6 days
Intervention | Participants (Count of Participants) |
---|---|
Personalized Pharmaceutical and Education (C) | 39 |
Placebo Pharmaceutical, General Education (B) | 32 |
Placebo Pharmaceutical, Personalized Education (A) | 32 |
Personalized Pharmaceutical, General Education (D) | 32 |
2 trials available for propranolol and Pain, Chronic
Article | Year |
---|---|
Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Autonomic Nervous System; Chronic Pain; Double-Blind Method; Facial Pain; F | 2021 |
Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Catastrophization; Catechol O-Methyltransferas | 2017 |